Early trial checks safety of blinatumomab in japanese leukemia patients
NCT ID NCT06649006
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested the safety of the drug blinatumomab (Blincyto®) in 6 Japanese adults newly diagnosed with a type of leukemia called B-ALL. The main goal was to see what side effects occurred. Researchers also looked at how the drug moves through the body and whether it helped achieve remission. Because it's a small, early trial, results are preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- blinatumomab (Blincyto®)
- What this could lead to
- If successful, this could support using blinatumomab as part of treatment for Japanese adults with B-ALL, potentially improving outcomes.
- What could go wrong
- This is a very small, early-phase trial (only 6 people) focused on safety, not effectiveness. Results may not apply to larger groups or show clear benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Akita University Hospital
Akita, Akita, 010-8543, Japan
-
Fukushima Medical University Hospital
Fukushima, Fukushima, 960-1295, Japan
-
Kanazawa University Hospital
Kanazawa, Ishikawa-ken, 920-8641, Japan
-
Kurume University Hospital
Kurume-shi, Fukuoka, 830-0011, Japan
-
Kyushu University Hospital
Fukuoka, Fukuoka, 812-8582, Japan
-
Yamagata University Hospital
Yamagata, Yamagata, 990-9585, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.